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Background-—Several clinical studies have evaluated the association between galectin-3 levels and outcome in patients with heart
failure (HF). However, little is known about the predictive value of repeated galectin-3 measurements. This study evaluates the
prognostic value of repeated time-dependent galectin-3 measurements in acute HF patients.
Methods and Results-—In the TRIUMPH (Translational Initiative on Unique and Novel Strategies for Management of Patients with
Heart Failure) clinical cohort study, 496 acute HF patients were enrolled in 14 hospitals in The Netherlands, between 2009 and
2014. Repeated blood samples (7) were drawn during 1-year follow-up. Associations between repeated biomarker measurements
and the primary end point were assessed using a joint model. Median age was 74 years and 37% were women. The primary end
point, composite of all-cause mortality and HF rehospitalization, was reached in 188 patients (40%), during a median follow-up of
325 days (interquartile range 85–401). The median baseline galectin-3 level was 24 ng/mL (interquartile range 18–34). The mean
number of galectin-3 measurements available per patient was 4.3. After adjustment for clinical factors and N-terminal pro-brain
natriuretic peptide, there was a weak association between baseline galectin-3 and risk of the primary end point. When repeated
measurements were taken into account, the adjusted hazard ratio per 1 SD increase of the galectin-3 level (on the log2 scale) at
any time point increased to 1.67 (95% conﬁdence interval, 1.24–2.23, P<0.001). After additional adjustment for repeated
N-terminal pro-brain natriuretic peptide measurements, the association remained statistically signiﬁcant.
Conclusions-—Repeated galectin-3 measurements appeared to be a strong predictor of outcome in acute HF patients, independent
of N-terminal pro-brain natriuretic peptide. Hence, galectin-3 may be helpful in clinical practice for prognostication and treatment
monitoring. ( J Am Heart Assoc. 2017;6:e003700. DOI: 10.1161/JAHA.116.003700.)
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M ost studies on serum biomarkers in heart failure (HF)populations conducted so far have related adverse
outcome during follow-up with a single measurement at
baseline.1–3 Although this approach has demonstrated the
prognostic value of a variety of biomarkers, among which are
the well-known natriuretic peptides,4 it does not explore the
biological variation within patients with evolving disease. In
fact, HF is a highly variable, heterogeneous, and progressive
condition.5 Thus, repeated biomarker measurements may be
required to more accurately reﬂect this dynamic and
progressive nature of the underlying pathophysiologic pro-
cesses, such as mechanical overload, atherosclerosis,
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inﬂammation, and cardiac ﬁbrosis. Therefore, we expect that
risk models that account for repeated measurements may
more adequately reﬂect the current status of the patient
compared with models that only use single measurements.
The TRIUMPH (Translational Initiative on Unique and Novel
Strategies for Management of Patients with Heart Failure)
study was designed to identify and validate novel biomarkers
to improve prognostication in HF.6 TRIUMPH was designed as
a translational study program, combining biological discovery
of novel biomarkers, technologic advances, and clinical
validation in patients presenting with acute HF. In the clinical
validation study, both the novel and established HF biomark-
ers were evaluated for their prognostic properties using a
unique design of 7 planned repeated measurements during
1-year follow-up. Based on previous clinical and epidemiolog-
ical studies, galectin-3 was earmarked as a biomarker with
high potential for improving prognostication.
Galectin-3 is a member of a large family of b-galactoside-
binding animal lectins.7 Galectin-3 expression has been
detected in macrophages, neutrophils, eosinophils, and mast
cells. In response to a variety of mechanical and neurohormonal
stimuli, macrophages secrete galectin-3.8 Galectin-3 stimulates
additional macrophages, pericytes, myoﬁbroblasts, and ﬁbrob-
lasts, which are all involved in the initiation and progression of
tissue scarring. Consequently, galectin-3 appears to be involved
in cardiac ﬁbrosis. In addition, galectin-3 plays an important role
in the inﬂammatory response, which is an important step in the
process of cardiac remodeling.9–11 Galectin-3 is expressed in
numerous tissues such as heart, kidney, lung, uterus, and
colon.12 The level of galectin-3 expression is relatively low in
heart tissue under normal conditions, but may increase
substantially under pathophysiological circumstances.13
Several clinical studies have evaluated the prognostic value
of galectin-3. Higher levels of galectin-3 have been associated
with an increased risk of incident HF and all-cause mortality in
the general population.14,15 Furthermore, single galectin-3 levels
have shown to be an independent risk factor of mortality in both
stable and acute HF patients, although it still remains uncertain
whether galectin-3 confers independent prognostic information
when added to N-terminal pro-brain natriuretic peptide
(NT-proBNP).2,3,16–18 A few studies have been performed to
assess the prognostic value of galectin-3 when measured
multiple times. The change in galectin-3 level over time was
predictive of outcome.19–21 However, given the dynamic and
progressive nature of HF, the number of galectin-3 measure-
ments needed for adequate estimation of the true galectin-3
level is expected to be high. Therefore, in the present study, we
assessed the independent association between the estimated
instantaneous galectin-3 level, using frequently measured
galectin-3 levels, and the incidence of all-cause mortality and
HF readmission during 1-year follow-up in the 496 patients with
acute HF who compose the TRIUMPH clinical cohort.
Methods
Objective and Study Design
TRIUMPH was designed as a translational bench-to-bedside
study program encompassing the entire spectrum of biomarker
discovery to clinical validation.6 The clinical validation study
was an observational prospective study enrolling patients
admitted with acute HF in 14 hospitals in The Netherlands,
between September 2009 and December 2013. This cohort
study was designed to validate the clinical value of biomarkers
successfully passing the bio-informatics and early-validation
stages of TRIUMPH, and to further evaluate more established
biomarkers of HF. There was a particular interest in the change
in biomarker levels over time. The study was approved by the
medical ethics committee at all participating centers.
Patient Selection
Patients ≥18 years of age were eligible for enrollment if they
were hospitalized with decompensation of known chronic HF
or newly diagnosed HF. Furthermore, 3 other criteria had to
be met: (1) natriuretic peptide levels had to be elevated to ≥3
times the upper limit of normal, (2) there had to be evidence
of sustained systolic or diastolic left ventricular dysfunction,
and (3) patients had to be treated with intravenous diuretics.
Patients with HF precipitated by a noncardiac condition, by
severe valvular dysfunction without sustained left ventricular
Clinical Perspective
What Is New?
• This study has a unique study design, including 7 measure-
ments scheduled during 1-year follow-up, along with a state-
of-the-art statistical approach using joint modeling to
evaluate the prognostic signiﬁcance of repeated galectin-3
measurements in acute heart failure patients.
What Are the Clinical Implications?
• This study demonstrates that repeated galectin-3 measure-
ments are a strong and independent predictor of adverse
outcome and offer incremental prognostic value to that
conferred by other known risk factors and, importantly,
repeated measurements of N-terminal pro-brain natriuretic
peptide.
• These results suggest that repeated galectin-3 measure-
ments in addition to repeated N-terminal pro-brain natri-
uretic peptide measurements may be used in clinical
practice to identify patients with heart failure who are at
increased risk of adverse outcome.
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dysfunction, or by an acute ST-segment elevation myocardial
infarction were excluded. Furthermore, patients scheduled for
a coronary revascularization procedure, on a waiting list for a
heart transplantation, with severe renal failure for which
dialysis was needed, or with a coexistent condition with a life
expectancy <1 year could not participate. All study partici-
pants provided written informed consent.
Patient Management
Patient management was at the discretion of the treating
physician, and in accordance with the guidelines of the
European Society of Cardiology.22 Importantly, the biomarker
data that were generated in the context of this observational
study were not used for treatment decisions.
Study Procedures
During hospitalization, blood samples were obtained at admis-
sion (day 1), once during days 2 to 4 and, subsequently, on the
day of discharge. Afterwards, repeated blood samples were
also obtained at outpatient follow-up visits, which were planned
at 2 to 4 weeks, 3 months, 6 months, and 9 to 12 months
after discharge. The baseline blood sample was deﬁned as the
ﬁrst sample obtained after inclusion, up to a maximum of
2 days after inclusion. At each visit, HF symptoms were
assessed using the New York Heart Association classiﬁcation.
Medication use was determined at discharge using 3 cate-
gories: (1) use of an angiotensin-converting enzyme inhibitor or
an angiotensin II receptor antagonist or both, (2) use of a
b-blocker, and (3) use of diuretics. Patients underwent physical
examination and systematic measurements of weight, blood
pressure, and heart rate.
Blood Collection
Nonfasting blood samples were obtained by venipuncture and
transported to the clinical chemistry laboratory of each
participating hospital for further processing according to a
standardized protocol. The collected material was centrifuged
at 1700g/relative centrifugal force, after which citrate-, EDTA-
, heparin-, and trasylol-plasma was separated, as well as blood
serum. Buffy coats were collected from EDTA tubes to enable
analysis of genetic factors. Dimethylsulfoxide was added to an
additional EDTA tube for cryopreservation of blood cells. All
blood aliquots were subsequently stored at a temperature of
80°C within 2 hours after venipuncture.
Galectin-3 Measurements
Serum and heparin-plasma were transported under con-
trolled conditions to a central laboratory (Future Diagnostics
Solutions B.V.) for batch analysis of galectin-3 and NT-
proBNP levels. Galectin-3 concentrations were determined
in serum, using the BGM Galectin-3 Test as instructed by
the manufacturer (BG Medicine, Inc, Waltham, MA). NT-
proBNP concentrations were determined in heparin plasma
using the Elecsys NT-proBNP assay on a Cobas 8000
analyzer (Roche Diagnostics Limited, Rotkreuz, Switzerland).
Analysts were blinded for patient characteristics and end
points.
End Points
Information on vital status and hospital readmissions was
obtained until at least 9 months with a maximum of 400 days
after the index hospitalization. We approached the civil
registry, screened all medical records, and asked patients for
information during their follow-up visits.
The primary end point is the composite of all-cause
mortality and readmission for HF. Readmission for HF was
deﬁned as an unplanned rehospitalization because of decom-
pensation of HF, with at least 2 of the following 3 criteria
being present: elevated natriuretic peptide levels ≥3 times the
upper limit of normal, symptoms of cardiac decompensation
(rales, edema, or elevated central venous pressure), and
treatment with intravenous diuretics. Secondary end points
included the individual components of the primary end point
and cardiovascular mortality. An event adjudication commit-
tee, blinded for biomarker information, was established for
reviewing and adjudication of end points.
Statistical Analysis
The distributions of continuous variables, including biomarker
levels, were evaluated for normality by visual examination of
the histogram and Kolmogorov–Smirnov tests. Variables with
a normal distribution are presented as mean SD, whereas
the median and interquartile range (IQR) are presented in case
of non-normality. Categorical variables are presented as
counts and percentages. Galectin-3 and NT-proBNP levels had
a non-normal distribution and were therefore log-transformed
for further analysis.
Patients were classiﬁed according to the quartiles of the
galectin-3 distribution, and differences in baseline character-
istics between these quartiles were evaluated by v2 tests
(categorical variables), analysis of variance, or Kruskal–Wallis
tests, as appropriate.
We applied Cox proportional hazards models to evaluate
the association of baseline galectin-3 levels with the study end
points. Subjects were censored at the time of occurrence of
the end point under investigation, death, and at the scheduled
end of follow-up. No deviations of the proportional hazards
assumption were found by inspecting log minus log plots of the
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survival functions. We performed univariate analyses to obtain
the crude estimates of the effect of baseline galectin-3 level
(model 1), analyses that were adjusted for age and sex only
(model 2), and analyses that were additionally adjusted for
systolic blood pressure, diabetes mellitus, left ventricular
ejection fraction, previous hospitalization for HF during the
past 6 months, ischemic HF, body mass index, estimated
glomerular ﬁltration rate, and baseline NT-proBNP level (model
3). The results are presented as adjusted hazard ratios (HR) per
1 SD increase of the biomarker level (on the log2 scale) with
95% conﬁdence intervals (CI). We calculated the estimated
glomerular ﬁltration rate using the Modiﬁcation of Diet in Renal
Disease equation.23
Joint models were ﬁtted to assess the association between
estimated instantaneous biomarker levels, calculated using
the repeated biomarker levels, and the speciﬁed study end
points. A joint model combines a mixed-effects linear
regression model for the serial measurements with a Cox
proportional hazards model for the risk of the speciﬁed study
end points.24 We used cubic splines, with knots set at 1 week
and 1 month after initial hospitalization. For the analyses with
the repeated galectin-3 measurements, we used similar
univariate and multivariate models as mentioned above
(models 1, 2, and 3), except for model 3 in which we added
medication use at discharge to the mixed-effects linear
regression model. We also tested whether the instantaneous
slope of the galectin-3 trajectories itself, when added to
model 3, was an independent predictor. Finally, we combined
the repeated measurements of galectin-3 and NT-proBNP to
assess their respective independent prognostic value. Taking
into account the limitations of the R packages for Joint
Modeling, we were able to combine the estimated galectin-3
trajectory (using a mixed-effects linear regression model) and
the estimated NT-proBNP trajectory (using a time-dependent
Cox proportional hazards model) in 1 joint model. Since the
model did not converge when we adjusted for all the
covariates in model 3, baseline systolic blood pressure had
to be left out in this ﬁnal model (model 4). Diagnostics and
sensitivity analyses were performed to evaluate the joint
models. To account for the correlation structure between
serial biomarker measurements collected from the same
patient, we obtained the SD from the total variance of a
random intercepts linear mixed model ﬁtted on the postdis-
charge data. The ﬁnal results are presented as adjusted HR
per 1 SD increase of the biomarker level (on the log2 scale) at
any point in time with 95% CI.
The TRIUMPH sample size was chosen to achieve a power of
80% (1b=0.8) to detect an odds ratio of at least 2.0 (a=0.05,
2-sided test) for a biomarker value above the 75% percentile of
its distribution comparing end point cases with noncases. The
incidence of the primary end point was initially estimated at
25% to 30%, based on observations in historical HF populations.
Then, 780 patients are required. During the course of the study,
based on evolving evidence, the estimated incidence was
adjusted to 30% to 35%, and the sample size was eventually
determined at 490 patients. TRIUMPH enrolled 496 patients,
and 40% reached the primary end point.
Data on covariates were complete in 93% of patients,
except for left ventricular ejection fraction, which
Table 1. Baseline Parameters According to Overall Sample in
Study Population (N=475)
Variables Overall Sample
Demographic characteristics, median (IQR) or %
Age, y 74 (65–80)
Female 37
White 95
Measurements at baseline, median (IQR) or %
Body mass index, kg/m2 28 (25–31)
Systolic blood pressure, mm Hg 125 (110–147)
Diastolic blood pressure, mm Hg 74 (65–85)
Heart rate, bpm 85 (72–100)
eGFR, mL/min per 1.73 m2 46 (34–62)
Left ventricular ejection fraction, % 30 (21–41)
NYHA classification
II 17
III 55
IV 27
Medical history, %
Newly diagnosed heart failure 36
Heart failure with reduced ejection fraction 83
Previous heart failure admission within 6 mo 20
Ischemic heart failure 49
Myocardial infarction 40
Hypertension 51
Atrial fibrillation 42
Diabetes mellitus 36
Stroke 17
Medication use at discharge, %
ACE-I and/or ARB 78
b-Blocker 78
Diuretics 93
Biomarkers, median (IQR)
Galectin-3, ng/mL 24 (18–34)
NT-proBNP, pg/mL 4152 (2089–9387)
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
antagonist; bpm, beats per minute; eGFR, estimated glomerular ﬁltration rate; IQR,
interquartile range; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York
Heart Association.
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was complete in 78%. Single imputation was applied to
account for missing values of covariates. Data are imputed
using predictive mean matching for continuous variables,
logistic regression for binary variables, and polytomous
regression for unordered categorical data. Baseline
covariates used in the full model and survival information
were used in the imputation. The software used was R
package MICE (https://cran.r-project.org/web/packages/
mice/mice.pdf). A sensitivity analyses was performed on
the full model for the primary end point on the complete
cases.
The Statistical Package for Social Sciences, version 21.0
(SPSS, IBM Corp., Armonk, NY) was used for descriptive
data analysis. R statistical software (version 2.15.0, avail-
able at: www.r-project.org) was used for advanced statis-
tical analyses of the longitudinal biomarker data and study
end points (packages JMBayes and JM). All statistical tests
were 2-tailed and P<0.05 were considered statistically
signiﬁcant.
Results
Patients
A total of 496 patients were enrolled in the TRIUMPH clinical
cohort. Three patients withdrew their informed consent.
Table 2. Baseline Characteristics According to Quartiles of Galectin-3 Level
Variables Quartile 1 Quartile 2 Quartile 3 Quartile 4 P Value*
Demographic characteristics, median or %
Age, y 70 73 76 75 0.010
Female 45 31 33 38 0.13
White 92 93 97 96 0.27
Measurements at baseline, median (IQR) or %
Body mass index, kg/m2 27 27 29 29 0.035
Systolic blood pressure, mm Hg 130 125 125 122 0.29
Diastolic blood pressure, mm Hg 80 73 74 70 <0.001
Heart rate, bpm 94 85 84 80 0.002
eGFR, mL/min per 1.73 m2 63 55 42 32 <0.001
Left ventricular ejection fraction, % 30 30 34 31 0.020
NYHA classification
II 23 18 11 14 0.12
III 50 51 63 60
IV 27 28 25 26
Medical history, %
Newly diagnosed heart failure 57 40 26 21 <0.001
Heart failure with reduced ejection fraction 88 88 76 81 0.080
Previous heart failure admission within 6 mo 8 17 24 29 <0.001
Ischemic heart failure 40 45 55 56 0.036
Myocardial infarction 28 32 54 48 <0.001
Hypertension 40 50 56 60 0.016
Atrial fibrillation 32 44 45 46 0.089
Diabetes mellitus 20 32 41 50 <0.001
Stroke 14 14 17 22 0.29
Biomarkers, median
NT-proBNP, pg/mL 3180 3970 4372 7544 <0.001
Galectin-3, ng/mL 16 21 28 40 <0.001
bpm indicates beats per minute; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart
Association.
*P value for differences between groups.
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Eighteen patients were withdrawn from statistical analyses
because of inclusion violation. These patients had no
evidence of sustained systolic or diastolic left ventricular
dysfunction on echocardiography. Accordingly, 475 patients
compose the analysis set. Their median age was 74 years
(IQR 65–80) and 37% were women (Table 1). Median systolic
blood pressure was 125 mm Hg (IQR 110–147) and median
left ventricular ejection fraction was 30% (IQR 21–41). At
discharge 78% used an angiotensin-converting enzyme
inhibitor or an angiotensin II receptor antagonist or both,
78% used a b-blocker, and 93% used diuretics. Median
baseline galectin-3 level was 24 ng/mL (IQR 18–34) and NT-
proBNP was 4152 pg/mL (IQR 2089–9387). Table 2 shows
the baseline characteristics of patients in different quartiles
of galectin-3 level. Patients in quartiles with a higher
galectin-3 level were older and had a worse kidney function.
In the higher galectin-3 quartiles, more patients had a
history of myocardial infarction and diabetes mellitus, had
ischemic HF, and had been admitted to the hospital for HF
during the past 6 months. In the lower galectin-3 quartiles,
more patients had newly diagnosed HF during the initial
hospitalization.
Baseline Galectin-3 Levels and the Incidence of
Study End Points
During the median follow-up of 325 days (IQR 85–401), 188
patients (40%) reached the primary composite end point of all-
cause death (n=113) or readmission for HF (n=123). This
corresponds with an incidence rate of 55.9 per 100 patient-
years for the primary end point. In the highest quartile of
baseline galectin-3, 65 patients (59%) reached the primary
Figure 1. Distributions of baseline galectin-3 levels within the subpopulations of patients who had an event and those who
did not experience an event for: (A) the primary end point; (B) the single end point of all-cause mortality; (C) the single end
point of readmission for heart failure; and (D) the single end point of cardiovascular mortality.
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end point compared with 27 patients (24%) in the lowest
quartile. The number of events in the highest quartile
compared with the lowest quartile of galectin-3 was also
higher for all-cause mortality (n=44 [40%] and n=14 [13%],
respectively) and readmission for HF (n=44 [40%] and n=19
[17%], respectively).
Baseline galectin-3 levels were higher in patients who
reached a study end point when compared with those who
remained event-free (Figure 1). The baseline galectin-3 level
was associated with an increased risk of reaching the primary
end point, as well as with all-cause mortality, cardiovascular
mortality, and HF readmission (Table 3). After adjustment for
all selected potential confounders including baseline NT-
proBNP level (model 3), the association between baseline
galectin-3 and the different end points became weaker, but
remained present.
Repeatedly Measured Galectin-3 Levels and the
Incidence of Study End Points
On average, galectin-3 was available 4.3 times during follow-
up. The mean galectin-3 level during follow-up was 23.8 ng/
mL; an increase of 1 SD galectin-3 level on the log2 scale
from the mean was 13 ng/mL. A decrease of 1 SD galectin-3
level on the log2 scale was 8 ng/mL. After adjustment for age
and sex (model 2), the HR per SD increase of the galectin-3
level (on the log2 scale) at any point in time was 2.09 (95% CI,
1.71–2.56) for the primary end point. After adjustment for the
broader range of potential confounders including medication
use at discharge and baseline NT-proBNP level (model 3), the
association remained highly statistically signiﬁcant with a HR
of 1.67 (95% CI, 1.24–2.23) (Table 4). Results were similar for
the secondary end points. The instantaneous slope of the
galectin-3 level trajectories itself was not an independent
predictor of the primary end point.
After adjustment for repeated NT-proBNP measurements
(model 4), the association between repeated galectin-3 levels
and adverse outcome remained statistically signiﬁcant with a
HR of 1.54 (95% CI, 1.16–2.05) for the primary end point
corresponding with 1 SD increase of galectin-3 level (on the
log2 scale) at any point in time (Table 5). The HR corre-
sponding with a 1-SD increase of NT-proBNP level (on the log2
scale) at any point in time was 2.10 (95% CI, 1.63–2.74) after
adjustment for repeated galectin-3 levels.
Figure 2A shows the average estimated galectin-3 level in
patients with and without the primary end point according to
model 3 and the individual galectin-3 measurements. During
hospitalization the average galectin-3 level remains steady for
patients who remained free of the primary end point. For
patients who reached the primary end point during follow-up,
the average estimated galectin-3 level decreased slightly after
the initial hospitalization. Apparently, throughout follow-up,
patients who reached the primary end point had, on average,
higher levels than their counterparts who remained free of the
primary end point. Furthermore, the average estimated
galectin-3 levels appeared to elevate several weeks before
the time of the primary end point (Figure 2B).
Discussion
This study clearly demonstrates that, in patients admitted
with acute HF, repeated galectin-3 measurements are a
strong and independent predictor of the composite end point
of all-cause mortality or readmission for HF during 1-year
follow-up. Our results illustrate that repeated measurements
of galectin-3 offer incremental prognostic value to (repeatedly
Table 3. Hazard Ratios for Different End Points Per 1 SD
Increase of the Baseline Galectin-3 Level (on the log2 Scale)
Mean Value* Baseline Level†
MSD M M+SD
HR (95% CI) P Value15.9 24.7 38.2
Primary end point
Model 1 1.50 (1.30–1.75) <0.001
Model 2 1.49 (1.28–1.73) <0.001
Model 3 1.12 (0.93–1.36) 0.241
Number of events/patients 188/475
All-cause mortality
Model 1 1.54 (1.29–1.85) <0.001
Model 2 1.52 (1.26–1.83) <0.001
Model 3 1.26 (1.01–1.59) 0.044
Number of events/patients 113/475
HF hospitalization
Model 1 1.47 (1.22–1.76) <0.001
Model 2 1.47 (1.23–1.76) <0.001
Model 3 1.05 (0.82–1.33) 0.720
Number of events/patients 123/475
Cardiovascular mortality
Model 1 1.60 (1.28–1.99) <0.001
Model 2 1.57 (1.26–1.97) <0.001
Model 3 1.24 (0.93–1.67) 0.147
Number of events/patients 77/475
Model 1 unadjusted; model 2 adjusted for age and sex; model 3 adjusted for age, sex,
systolic blood pressure, diabetes mellitus, LVEF, previous hospitalization for heart failure
during the past 6 mo, ischemic heart failure, body mass index, eGFR, and baseline
NT-proBNP. CI indicates conﬁdence interval; eGFR, estimated glomerular ﬁltration rate;
HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; M, mean;
NT-proBNP, N-terminal pro-brain natriuretic peptide.
*Mean1 SD of the patient-speciﬁc geometric mean galectin-3 value at baseline
(presented on the linear scale).
†Hazard ratios are related to a 1-SD increase of galectin-3 (on the log scale) at baseline.
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measured) NT-proBNP, which is considered the criterion
standard biomarker in HF patients.
Our observation that baseline galectin-3 level was associ-
ated with mortality conﬁrms earlier ﬁndings both in acute and
stable HF patients.2,3,25,26 Similar to previous studies, the
association between baseline galectin-3 level and mortality
attenuated after adjustment for established risk factors,
including kidney function and NT-proBNP level.16,17,27 The
association between baseline galectin-3 level and readmission
for HF was less apparent. However, the decision to hospitalize
a patient for decompensation of HF may be inﬂuenced by
several subjective patient- and physician-related factors that
are unlikely to have an association with the galectin-3 level.
Furthermore, several risk factors such as kidney function,
diabetes mellitus, and NT-proBNP level inﬂuence this decision
and are related to galectin-3. Therefore, the association
between baseline galectin-3 level and HF readmission atten-
uated after adjustment for these risk factors. Since the
primary end point is a composite of all-cause mortality and
readmission for HF, the relationship between the galectin-3
level and the mortality end points per se are stronger
compared with the primary end point.
Repeated galectin-3 measurements were strongly and
independently related to the primary end point, as well as its
separate components. Repeated measurements take into
account the dynamic and continuous change in galectin-3
level over time, which better reﬂects the true nature of the
underlying pathophysiology in HF. In this study, the number of
galectin-3 measurements per patient was high and therefore
the repeated galectin-3 measurements could be used to
estimate instantaneous galectin-3 levels (ie, the estimated
galectin-3 level at any point in time during the follow-up
period). When compared with baseline galectin-3 levels, the
estimated instantaneous galectin-3 levels identiﬁed patients
at an even higher risk for reaching an end point. The
estimated instantaneous galectin-3 level more accurately
approximates the true galectin-3 level and therefore reﬂects
the actual condition of the patient at that point in time during
follow-up. This is expected to be important since HF is a
dynamic and often progressive disease in which inﬂammation,
cardiac ﬁbrosis, and remodeling are ongoing processes that
cannot be captured in a single biomarker assessment at 1
point in time.5 Furthermore, baseline galectin-3 measure-
ments were all taken during hospitalization for
Table 4. Hazard Ratios for Different End Points Per 1 SD Increase of the Galectin-3 Level (on the log2 Scale) at Any Point in Time,
Using a Joint Model
Mean Value* Instantaneous Level†
MSD M M+SD HR (95% CI) P Value
Primary end point 15.4 23.8 36.6
Model 1 2.07 (1.71–2.53) <0.001
Model 2 2.09 (1.71–2.56) <0.001
Model 3 1.67 (1.24–2.23) <0.001
All-cause mortality 15.4 23.8 36.9
Model 1 2.41 (1.83–3.15) <0.001
Model 2 2.36 (1.78–3.08) <0.001
Model 3 2.14 (1.47–3.16) <0.001
HF hospitalization 15.4 23.8 36.6
Model 1 1.87 (1.47–2.39) <0.001
Model 2 1.92 (1.48–2.46) <0.001
Model 3 1.41 (1.02–1.93) 0.035
Cardiovascular mortality 15.4 23.8 36.9
Model 1 2.46 (1.79–3.34) <0.001
Model 2 2.43 (1.76–3.35) <0.001
Model 3 2.22 (1.48–3.36) <0.001
Model 1 unadjusted; model 2 adjusted for age and sex; model 3 adjusted for age, sex, systolic blood pressure, diabetes mellitus, LVEF, previous hospitalization for HF during the past 6 mo,
ischemic HF, body mass index, eGFR, medication use at hospital discharge (ACE-I and/or ARB, b-blocker, and diuretics) and baseline NT-proBNP level. ACE-I indicates angiotensin-
converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; HF, heart failure; HR, hazard ratio; LVEF, left
ventricular ejection fraction; M, mean; NT-proBNP, N-terminal pro-brain natriuretic peptide.
*Mean1 SD of the patient-speciﬁc geometric mean galectin-3 value during follow-up (presented on the linear scale).
†HRs are related to a 1-SD increase of galectin-3 (on the log scale) at any point in time.
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decompensated chronic HF or new-onset HF. It is known that
galectin-3, in contrast to natriuretic peptides, does not
respond to volume overload and unloading directly, which
occurs during hospitalization.28 As galectin-3 is involved in the
process of myocardial ﬁbrosis, it is more likely that galectin-3
is of more prognostic value when patients enter a more
chronic phase of HF.11
Interestingly, the slope of the galectin-3 trajectory did not
add prognostic information to the estimated instantaneous
galectin-3 level. An explanation could be that galectin-3 is
helpful in identifying high-risk patients when their galectin-3
level rises above a certain threshold. The change in galectin-3
level before reaching this threshold is not essential for risk
stratiﬁcation. However, to be able to estimate whether a
patient’s galectin-3 level rises above the threshold, repeated
measurements are required. A few studies have been
conducted on the prognostic value of multiple galectin-3
measurements in acute and stable HF patients.19,20 These
studies showed that change in galectin-3 level is associated
with mortality. A possible explanation as to why in the present
study slope of the galectin-3 trajectory did not add further
prognostic information might be that the number of galectin-3
measurements during follow-up was substantially higher in
our study, which allowed us to estimate an instantaneous
slope of the galectin-3 trajectory, rather than the slope of the
Table 5. Hazard Ratios for Different End Points Per 1-SD
Increase of Galectin-3 Level or NT-proBNP Level (on the log2
Scale) at Any Point in Time Using Repeated Galectin-3 and
NT-proBNP Measurements in a Joint Model
Mean Value* Instantaneous Level†
MSD M M+SD HR (95% CI) P Value
Primary end point
Galectin-3 15.4 23.8 36.6 1.54 (1.16–2.05) 0.003
NT-proBNP 742 2445 8062 2.10 (1.63–2.74) <0.001
All-cause mortality
Galectin-3 15.4 23.8 36.9 1.77 (1.22–2.52) <0.001
NT-proBNP 739 2480 8321 2.68 (1.90–3.86) <0.001
HF hospitalization
Galectin-3 15.4 23.8 36.6 1.29 (0.92–1.81) 0.160
NT-proBNP 742 2445 8062 1.71 (1.27–2.25) <0.001
Cardiovascular mortality
Galectin-3 15.4 23.8 36.9 1.89 (1.25–2.85) 0.002
NT-proBNP 739 2480 8321 2.62 (1.70–4.27) <0.001
Model 4 adjusted for age, sex, diabetes mellitus, LVEF, previous hospitalization for heart
failure during the past 6 mo, ischemic heart failure, body mass index, eGFR, medication
use at hospital discharge (ACE-I and/or ARB, b-blocker, and diuretics) and baseline NT-
proBNP level. ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin
II receptor antagonist; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate;
HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; M, mean; NT-
proBNP, N-terminal pro-brain natriuretic peptide.
*Mean1 SD of the patient-speciﬁc geometric mean biomarker level during follow-up
(presented on the linear scale).
†Hazard ratios are related to a 1-SD increase of biomarker level (on the log scale) at any
point in time.
A
B
Figure 2. A, Average estimated galectin-3 pattern during
initial hospitalization for decompensated heart failure for
patients with and without the primary end point. The ﬁgure
includes the individual galectin-3 measurements for patients
with and without the primary end point. B, Average estimated
galectin-3 pattern before the primary end point or end of
follow-up for patients with and without the primary end point.
The ﬁgure includes the individual galectin-3 measurements for
patients with and without the primary end point. The average
estimated galectin-3 levels are adjusted for age, sex, systolic
blood pressure, diabetes mellitus, LVEF, previous hospitalization
for heart failure during the past 6 months, ischemic heart
failure, body mass index, eGFR, medication use at hospital
discharge (ACE-I and/or ARB, b-blocker, and diuretics), and
baseline NT-proBNP (model 3). ACE-I indicates angiotensin-
converting enzyme inhibitor; ARB, angiotensin II receptor
antagonist; eGFR, estimated glomerular ﬁltration rate; LVEF,
left ventricular ejection fraction; NT-proBNP, N-terminal
pro-brain natriuretic peptide.
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difference (“delta”) between the level at baseline and that at a
ﬁxed point in time.
The statistical method (Joint Model) used to estimate the
trajectory of the galectin-3 level takes into account the
continuous changes in biomarker levels and adequately
analyzes the relation between these biomarker trajectories
and different end points considering the changing population
because of censoring at the time of occurrence of an end point.
Previous studies presented changes in biomarker level as a
“delta” between just 2 measurements that are separated in
time. If >2 samples are taken into account, patients have often
been categorized according to the number of high or low
biomarker levels. Obviously, both approaches do not fully
capture the true biomarker pattern of the dynamic disease.
Additionally, the power to predict adverse outcome is reduced.
An important ﬁnding of the present study is that repeated
galectin-3 measurements conferred additional and indepen-
dent prognostic information to that offered by baseline as well
as repeated NT-proBNP measurements. The fact that NT-
proBNP and galectin-3 reﬂect different underlying pathophys-
iological processes in HF may be the most important reason
for this observation. Galectin-3 is a marker of cardiac ﬁbrosis,
inﬂammation, and remodeling, whereas NT-proBNP is a
marker of volume overload.13,29 As such, galectin-3 might
be a marker that more directly reﬂects the pathophysiological
processes that lead to adverse cardiac remodeling and
deterioration of cardiac function, whereas NT-proBNP reﬂects
the volume overload resulting from the actual (left) ventricular
dysfunction. In this way, the galectin-3 and NT-proBNP level
provide complementary information on the pathophysiological
state, as well as with respect to the assessment of prognosis.
With respect to prognostication in HF, the results of the
present study, therefore, not only provide evidence for the use
of repeated galectin-3 measurements, but also for the
combined use with (repeatedly measured) NT-proBNP.
Although this study is a large multicenter prospective
observational study, it seems that the studied population is
not completely representative for the average HF population.
The mean age in our study population is 74 years and the
women are underrepresented. Moreover, only 18% of the
included HF patients have a preserved ejection fraction. de
Boer et al30 showed that galectin-3 levels did not differ
between HF patients with a reduced and preserved ejection
fraction and the predictive value of galectin-3 was stronger in
patients with a preserved ejection fraction. By under-
representing the HF patients with a preserved ejection
fraction in our study, we possibly underestimated the
prognostic value of galectin-3.
Future studies should evaluate the value of repeated
galectin-3 measurements when used to guide treatment
decisions. It may be hypothesized that treatment is to be
intensiﬁed in patients with high galectin-3 levels or unfavorable
galectin-3 patterns. On the other hand, repeated galectin-3
measurements might be helpful to identify patients who are
more likely to respond to certain treatments.31 Furthermore, it
remains to be addressed whether galectin-3may be targeted by
speciﬁc antigalectin-3 therapies. Additional studies should also
determine the number of galectin-3 measurements needed for
optimal prognostication and therapy monitoring. The frequency
by which galectin-3 levels should be measured may not be
identical for each patient, but depends on the clinical condition
of the patient, the treatment given, the galectin-3 level, and the
progression of galectin-3 levels during follow-up.
Conclusions
The TRIUMPH study clearly demonstrates that repeated
measurements of galectin-3 are a strong and independent
predictor of adverse outcome in patients following admission
for acute HF. The estimated instantaneous galectin-3 level
identiﬁed patients at a higher risk of reaching adverse events
than baseline galectin-3 levels alone. In addition, repeated
galectin-3 measurements offer incremental prognostic value
to that conferred by other known risk factors and, impor-
tantly, repeated measurements of NT-proBNP. These results
suggest that repeated galectin-3 measurements in addition to
NT-proBNP measurements may be helpful in clinical practice
to identify HF patients who are at increased risk of adverse
outcome.
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